Insulin-like growth factor binding proteins IGFBP3, IGFBP4, and IGFBP5 predict endocrine responsiveness in patients with ovarian cancer

Graeme Walker, Kenneth MacLeod, Alistair R W Williams, David A Cameron, John F Smyth, Simon P Langdon

Research output: Contribution to journalArticlepeer-review

Abstract

This study sought to explore the predictive value of the insulin-like growth factor (IGF) binding proteins (IGFBP) as markers of response in ovarian cancer patients treated with the aromatase inhibitor letrozole.
Original languageEnglish
Pages (from-to)1438-44
Number of pages7
JournalClinical Cancer Research
Volume13
Issue number5
DOIs
Publication statusPublished - 1 Mar 2007

Keywords

  • Antineoplastic Agents
  • CA-125 Antigen
  • Cell Line, Tumor
  • Drug Resistance, Neoplasm
  • Estradiol
  • Female
  • Humans
  • Immunohistochemistry
  • Insulin-Like Growth Factor Binding Protein 3
  • Insulin-Like Growth Factor Binding Protein 4
  • Insulin-Like Growth Factor Binding Protein 5
  • Insulin-Like Growth Factor Binding Proteins
  • Nitriles
  • Ovarian Neoplasms
  • RNA, Messenger
  • Receptors, Estrogen
  • Reverse Transcriptase Polymerase Chain Reaction
  • Triazoles

Fingerprint

Dive into the research topics of 'Insulin-like growth factor binding proteins IGFBP3, IGFBP4, and IGFBP5 predict endocrine responsiveness in patients with ovarian cancer'. Together they form a unique fingerprint.

Cite this